Transparency data

Aggregate net sales and payment information: 16 November 2020 (corrected)

Updated 1 February 2021

Table 1: unaudited sales reports: measured sales

Year	2019 voluntary scheme	Statutory scheme	Parallel imports	Total
2018 Q1	£2,150m	£394m	£170m	£2,714m
2018 Q2	£2,191m	£415m	£182m	£2,787m
2018 Q3	£2,237m	£422m	£189m	£2,849m
2018 Q4	£2,285m	£425m	£195m	£2,905m
2018	£8,855m	£1,654m	£736m	£11,246m
2019 Q1	£2,195m	£411m	£183m	£2,789m
2019 Q2	£2,178m	£422m	£170m	£2,769m
2019 Q3	£2,304m	£419m	£165m	£2,888m
2019 Q4	£2,400m	£423m	£179m	£3,002m
2019	£9,081m	£1,671m	£697m	£11,449m
2020 Q1	£2,747m	£99m	£191m	£3,037m
2020 Q2	£2,406m	£95m	£176m	£2,678m
2020 Q3	£2,620m	£87m	£198m	£2,905m

Table 1 notes

1. Table 1 sets out aggregate information about measured sales subject to the affordability mechanism. It includes information received on parallel imports and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 voluntary scheme and the statutory scheme.

2. The baseline for measured sales in respect of the statutory scheme and parallel imports has been calculated in accordance with annex 4, paragraph 1 of the 2019 voluntary scheme.

3. Measured sales is defined in the glossary of the 2019 voluntary scheme for branded medicines pricing and access as “sales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales”.

4. Figures for the 2019 voluntary scheme reflect any audited sales reports received. Annual totals from 2019 onwards for the statutory scheme reflect any audited sales reports received.

Measured sales in any particular period reflects all relevant scheme members in either the 2019 voluntary scheme or statutory scheme during that period. For example, several companies moved from the statutory scheme to the voluntary scheme at the start of 2020. Those companies’ measured sales will appear under the statutory scheme in 2019 but the voluntary scheme in 2020.

Table 2: 2019 voluntary scheme sales reports: eligible sales and resulting total scheme payments

Period	Aggregate eligible sales	Resulting aggregate scheme payments
2019 Q1	£2,069m	£199m
2019 Q2	£2,114m	£203m
2019 Q3	£2,258m	£217m
2019 Q4	£2,340m	£225m
2019	£8,785m	£843m
2020 Q1	£2,542m	£150m
2020 Q2	£2,286m	£135m
2020 Q3	£2,495m	£147m

Table 2 notes

Table 2, which is derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2019 voluntary scheme, sets out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments.

There are 2 columns of information:

• column 1: aggregate eligible sales
• column 2: resulting aggregate scheme payments due for the respective periods

Note: eligible sales is defined in the glossary of the 2019 voluntary scheme as “sales of scheme products but excluding exemptions from eligible sales”. The percentage payment applies to these sales. Eligible sales excludes certain types of sales, including the first £5 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.

Table 3: statutory scheme sales reports ‒ net sales covered by the statutory scheme payment and resulting payments 

Statutory scheme payment and resulting payments	Jan to Mar 2019	Apr to Jun 2019	Jul to Sep 2019	Oct to Dec 2019	2019
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	£140m	£137m	£173m	£191m	£633m
Resulting aggregate statutory scheme payment (b)	£14m	£14m	£17m	£19m	£63m
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	£53m	£85m	£81m	£76m	£308m
Resulting statutory scheme 7.8% payment (d)	£4m	£7m	£6m	£6m	£24m
Total resulting statutory scheme payment (b + d)	£18m	£20m	£24m	£25m	£87m

Statutory scheme payment and resulting payments	Jan to Mar 2020	Apr to Jun 2020	Jul to Sep 2020
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	£5m	£7m	£9m
Resulting aggregate statutory scheme payment (b)	£1m	<£1m	<£1m
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	£4m	£4m	£4m
Resulting statutory scheme 7.8% payment (d)	<£1m	<£1m	<£1m
Total resulting statutory scheme payment (b + d)	£1m	£1m	£1m

Table 3 notes

Table 3 is derived from audited and unaudited statutory scheme sales reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: the information in all tables is that held on the Department of Health and Social Care’s database at 16 November 2020 (corrected).

Note 2: totals may not sum due to rounding.

Note 3: all tables are subject to future correction such as where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26 to 4.31 of the 2019 voluntary scheme. The statutory scheme audit requirements are set out at paragraph 23 of the regulations.

Note 4: This document replaces the previous version which was published in December 2020. Following continual data checks, this replacement contains corrections to some of the information.